奧昔組單抗，Otelixizumab，CAS:881191-44-2， AntibodySystem Laboratories

貨號：DHC27702

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75400.html

別名：ChAglyCD, TRX4, CAS: 881191-44-2

簡介：奧昔組單抗Otelixizumab (ChAglyCD3)是一種抗人CD3單克隆抗體，可用于1型糖尿病的研究

貨號：DHC27702

產(chǎn)品品牌：Antibodysystem

通用名：Otelixizumab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：ChAglyCD, TRX4

靶點;物種：Human CD3E

種類：Chimeric/Humanized

受體鑒定：IgG1-lambda

CAS: 881191-44-2

存儲條件：

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

參考文獻：

Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus. PMID: 21913874

Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus. PMID: 27145230

Targeting T cells in inflammatory bowel disease. PMID: 32585338

Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. PMID: 27161438

Anti-CD3 monoclonal antibodies for the prevention and treatment of type 1 diabetes: A literature review. PMID: 36056809

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. PMID: 21719095

A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes. PMID: 33145642

Otelixizumab in the treatment of type 1 diabetes mellitus. PMID: 22053883

Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes. PMID: 34936848

Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients. PMID: 30566758

Molecule of the month. Otelixizumab. PMID: 20520855

Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. PMID: 25011949

Temporal pharmacokinetic/pharmacodynamic interaction between human CD3ε antigen-targeted monoclonal antibody otelixizumab and CD3ε binding and expression in human peripheral blood mononuclear cell static culture. PMID: 26341624

Urinary C-peptide analysis in an intervention study: experience from the DEFEND-2 otelixizumab trial. PMID: 26871270

Subcutaneous Administration of Otelixizumab is Limited by Injection Site Reactions: Results of an Exploratory Study in Type 1 Diabetes Mellitus Patients. PMID: 27023009

Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus. PMID: 19934031

Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study. PMID: 24236828

Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. PMID: 20147616

Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes. PMID: 25583753

Prospects for therapeutic tolerance in humans. PMID: 24378931

Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases. PMID: 23254986

Immunomodulators: Cell savers. PMID: 22616095

A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease. PMID: 24704524

Biologic therapies in type 1 diabetes: how far are they from us? PMID: 24229664

Immunotherapies in diabetes mellitus type 1. PMID: 22703858

Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice. PMID: 29030662

Anti-CD3 Antibody for the Prevention of Type 1 Diabetes: A Story of Perseverance. PMID: 31523950

Anti-CD3 clinical trials in type 1 diabetes mellitus. PMID: 23726024

Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. PMID: 21289272

Studies in human intestinal tissues: is it time to reemphasize research in human immunology? PMID: 24877864

Anti-CD3 mAbs for treatment of type 1 diabetes. PMID: 19319985

Emerging treatments for the prevention of type 1 diabetes. PMID: 20384544

Type 1 diabetes pathogenesis - Prevention??? PMID: 25941654

CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic. PMID: 23804274

Clinical update on the use of immuno modulators (antiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes. PMID: 21864261

Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients. PMID: 22069286

[Antibodies instead of insulin?]. PMID: 20196056

Antibody-based therapeutics to watch in 2011. PMID: 21051951

Prevention and reversal of type 1 diabetes--past challenges and future opportunities. PMID: 25998292

Anti-CD3 antibodies for type 1 diabetes: beyond expectations. PMID: 21719098

Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes. PMID: 29925930

Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration. PMID: 26073995

Methods to measure the binding of therapeutic monoclonal antibodies to the human Fc receptor FcγRIII (CD16) using real time kinetic analysis and flow cytometry. PMID: 22366323

Development of a quantitative assay to measure EBV viral load in patients with autoimmune type 1 diabetes and healthy subjects. PMID: 19931313